Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Kolb EA"" wg kryterium: Autor


Tytuł:
Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling.
Autorzy:
Kolb EA
Gorlick R
Keir ST
Maris JM
Lock R
Carol H
Kurmasheva RT
Reynolds CP
Kang MH
Wu J
Houghton PJ
Smith MA
Kolb, E Anders
Gorlick, Richard
Keir, Stephen T
Maris, John M
Lock, Richard
Carol, Hernan
Kurmasheva, Raushan T
Reynolds, C Patrick
Pokaż więcej
Źródło:
Pediatric Blood & Cancer; May2012, Vol. 58 Issue 5, p815-818, 4p
Czasopismo naukowe
Tytuł:
Association of the social disorganization index with time to first septic shock event in children with acute myeloid leukemia.
Autorzy:
Ruiz J; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Li Y; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Cao L; Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Huang YV; Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Tam V; Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Griffis HM; Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Winestone LE; Division of Allergy, Immunology, and Bone Marrow Transplantation, Benioff Children's Hospital, University of California San Francisco, San Francisco, California, USA.
Fisher BT; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.; Division of Infectious Diseases, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Alonzo TA; Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Wang YJ; Public Health Institute, Monrovia, California, USA.
Dang AT; Public Health Institute, Monrovia, California, USA.
Kolb EA; Nemours Center for Cancer and Blood Disorders, Nemours Children's Health, Wilmington, Delaware, USA.
Glanz K; Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Getz KD; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.; Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Aplenc R; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Seif AE; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Pokaż więcej
Źródło:
Cancer [Cancer] 2024 Mar 15; Vol. 130 (6), pp. 962-972. Date of Electronic Publication: 2023 Nov 20.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Shock, Septic*/epidemiology
Shock, Septic*/complications
Leukemia, Myeloid, Acute*/therapy
Child ; Humans ; Anomie ; Proportional Hazards Models ; Recurrence
Czasopismo naukowe
Tytuł:
Down syndrome and leukemia: An insight into the disease biology and current treatment options.
Autorzy:
Barwe SP; Lisa Dean Moseley Institute for Cancer and Blood Disorders, Nemours Children's Health, Wilmington, Delaware, 19803, USA.
Kolb EA; Lisa Dean Moseley Institute for Cancer and Blood Disorders, Nemours Children's Health, Wilmington, Delaware, 19803, USA.
Gopalakrishnapillai A; Lisa Dean Moseley Institute for Cancer and Blood Disorders, Nemours Children's Health, Wilmington, Delaware, 19803, USA. Electronic address: .
Pokaż więcej
Źródło:
Blood reviews [Blood Rev] 2024 Mar; Vol. 64, pp. 101154. Date of Electronic Publication: 2023 Nov 25.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Down Syndrome*/complications
Down Syndrome*/genetics
Down Syndrome*/therapy
Leukemia, Megakaryoblastic, Acute*/drug therapy
Leukemia, Megakaryoblastic, Acute*/genetics
Child ; Animals ; Humans ; GATA1 Transcription Factor/genetics ; Mutation ; Recurrence ; Biology
Czasopismo naukowe
Tytuł:
CD74 is expressed in a subset of pediatric acute myeloid leukemia patients and is a promising target for therapy: a report from the Children's Oncology Group.
Autorzy:
Menssen AJ; Hematologics Inc., Seattle, WA. .
Hudson CA; Hematologics Inc., Seattle, WA.
Alonzo T; Children's Oncology Group, Monrovia, CA, USA; Department of Preventive Medicine, University of Southern California, Los Angeles, CA.
Gerbing R; Children's Oncology Group, Monrovia, CA.
Pardo L; Hematologics Inc., Seattle, WA.
Leonti A; Fred Hutchinson Cancer Research Center, Seattle WA.
Cook JA; Hematologics Inc., Seattle, WA.
Hsu FC; Hematologics Inc., Seattle, WA.
Lott LL; Hematologics Inc., Seattle, WA.
Dai F; Hematologics Inc., Seattle, WA.
Fearing C; Hematologics Inc., Seattle, WA.
Ghirardelli K; Hematologics Inc., Seattle, WA.
Hylkema T; Fred Hutchinson Cancer Research Center, Seattle WA.
Tarlock K; Fred Hutchinson Cancer Research Center, Seattle WA, USA; Seattle Children's Hospital, Cancer and Blood Disorders Center, Department of Hematology/Oncology, Seattle, WA.
Loeb KR; Fred Hutchinson Cancer Research Center, Seattle WA, USA; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA.
Kolb EA; Children's Oncology Group, Monrovia, CA, USA; Nemours Center for Cancer and Blood Disorders Nemours/A.I. DuPont Hospital for Children, Wilmington DE.
Cooper T; Seattle Children's Hospital, Cancer and Blood Disorders Center, Department of Hematology/Oncology, Seattle, WA.
Pollard J; Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA.
Wells DA; Hematologics Inc., Seattle, WA.
Loken MR; Hematologics Inc., Seattle, WA.
Aplenc R; Children's Hospital of Philadelphia, Philadelphia, PA.
Meshinchi S; Children's Oncology Group, Monrovia, CA, USA; Fred Hutchinson Cancer Research Center, Seattle WA.
Brodersen LE; Hematologics Inc., Seattle, WA.
Pokaż więcej
Źródło:
Haematologica [Haematologica] 2024 Feb 01. Date of Electronic Publication: 2024 Feb 01.
Typ publikacji:
Journal Article
Czasopismo naukowe
Tytuł:
Treatment outcomes of childhood PICALM::MLLT10 acute leukaemias.
Autorzy:
Mark C; Division of Hematology/Oncology, Toronto Hospital for Sick Children, Toronto, Ontario, Canada.
Meshinchi S; Fred Hutchinson Cancer Research Centre, Seattle, Washington, USA.
Joyce B; Division of Hematology/Oncology, Toronto Hospital for Sick Children, Toronto, Ontario, Canada.
Gibson B; Royal Hospital for Sick Children, Glasgow, Scotland, UK.
Harrison C; Newcastle University Centre for Cancer, Newcastle, UK.
Bergmann AK; Human Genetics, Hannover Medical School, Hannover, Germany.
Goemans BF; Princess Maxima Centre for Pediatric Oncology, Utrecht, The Netherlands.
Pronk CJH; Skane University Hospital, Lund, Sweden.
Lapillonne H; Hôpital d'enfants Armand Trousseau, Paris, France.
Leverger G; Hôpital d'enfants Armand Trousseau, Paris, France.
Antoniou E; Universitats-Klinikum, Essen, Germany.
Schneider M; Universitats-Klinikum, Essen, Germany.
Attarbaschi A; Department of Pediatrics and Adolescent Medicine, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria.; St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria.
Dworzak M; Department of Pediatrics and Adolescent Medicine, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria.; St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria.
Stary J; Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
Tomizawa D; Division of Leukemia and Lymphoma, Children's Cancer Centre, National Centre for Child Health and Development, Tokyo, Japan.
Ebert S; Clinic of Pediatric Hematology and Oncology, University Medical Centre, Hamburg, Germany.
Lejman M; Independent Laboratory of Genetic Diagnostics, Medical University of Lublin, Lublin, Poland.
Kolb EA; Nemours Children's Hospital, Wilmington, Delaware, USA.
Schmiegelow K; Rigshospitalet University Hospital, Copenhagen, Denmark.
Hasle H; Hematology/Oncology, Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark.
Abla O; Division of Hematology/Oncology, Toronto Hospital for Sick Children, Toronto, Ontario, Canada.
Pokaż więcej
Źródło:
British journal of haematology [Br J Haematol] 2024 Feb; Vol. 204 (2), pp. 576-584. Date of Electronic Publication: 2023 Sep 24.
Typ publikacji:
Multicenter Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Leukemia, Myeloid, Acute*/genetics
Monomeric Clathrin Assembly Proteins*/genetics
Child ; Humans ; In Situ Hybridization, Fluorescence ; Retrospective Studies ; Oncogene Proteins, Fusion/genetics ; Treatment Outcome ; Transcription Factors/genetics ; Acute Disease ; Prognosis
Czasopismo naukowe
Tytuł:
The PedAL/EuPAL Project: A Global Initiative to Address the Unmet Medical Needs of Pediatric Patients with Relapsed or Refractory Acute Myeloid Leukemia.
Autorzy:
Ceolin V; Princess Máxima Center for Pediatric Oncology, 3584 Utrecht, The Netherlands.; Department of Pediatric Hematology/Oncology, Regina Margherita Children's Hospital, University of Turin, 10126 Turin, Italy.
Ishimaru S; Princess Máxima Center for Pediatric Oncology, 3584 Utrecht, The Netherlands.
Karol SE; Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Bautista F; Princess Máxima Center for Pediatric Oncology, 3584 Utrecht, The Netherlands.; The Innovative Therapies for Children with Cancer (ITCC) Consortium, 94805 Paris, France.
Goemans BF; Princess Máxima Center for Pediatric Oncology, 3584 Utrecht, The Netherlands.
Gueguen G; Center of Clinical Investigations, INSERM CIC 1426, Robert Debre Hospital, University of Paris, 75019 Paris, France.
Willemse M; Princess Máxima Center for Pediatric Oncology, 3584 Utrecht, The Netherlands.
Di Laurenzio L; Leukemia & Lymphoma Society, Rye Brook, NY 10573, USA.
Lukin J; Leukemia & Lymphoma Society, Rye Brook, NY 10573, USA.
van Tinteren H; Princess Máxima Center for Pediatric Oncology, 3584 Utrecht, The Netherlands.
Locatelli F; Department of Hematology/Oncology and Cell and Gene Therapy, IRCCS Bambino Gesù Children's Hospital, Catholic University of the Sacred Heart, 00163 Rome, Italy.
Petit A; Department of Pediatric Hematology and Oncology, Hôpital Armand Trousseau, Assistance Publique Hôpitaux de Paris, APHP Sorbonne Université, 75012 Paris, France.
Tomizawa D; Division of Leukemia and Lymphoma, Children's Cancer Center, National Center for Child Health and Development, Tokyo 104-0045, Japan.
Norton A; Birmingham Children's Hospital, Birmingham B4 6NH, UK.
Kaspers G; Princess Máxima Center for Pediatric Oncology, 3584 Utrecht, The Netherlands.; Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit, 1105 Amsterdam, The Netherlands.
Reinhardt D; Department of Pediatric Hematology/Oncology, Pediatrics III, University Hospital of Essen, 45147 Essen, Germany.
Tasian SK; Division of Oncology, Children's Hospital of Philadelphia, Department of Pediatrics, School of Medicine, Center for Childhood Cancer Research, University of Pennsylvania, Philadelphia, PA 19104, USA.
Nichols G; Leukemia & Lymphoma Society, Rye Brook, NY 10573, USA.
Kolb EA; Leukemia & Lymphoma Society, Rye Brook, NY 10573, USA.
Zwaan CM; Princess Máxima Center for Pediatric Oncology, 3584 Utrecht, The Netherlands.; The Innovative Therapies for Children with Cancer (ITCC) Consortium, 94805 Paris, France.; Department of Pediatric Hematology/Oncology, Erasmus University MC-Sophia Children's Hospital, 3015 Rotterdam, The Netherlands.
Cooper TM; Division of Hematology/Oncology, Seattle Children's Hospital, University of Washington, Seattle, DC 98105, USA.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2023 Dec 22; Vol. 16 (1). Date of Electronic Publication: 2023 Dec 22.
Typ publikacji:
Journal Article
Czasopismo naukowe
Tytuł:
Therapeutic targeting in pediatric acute myeloid leukemia with aberrant HOX/MEIS1 expression.
Autorzy:
Juul-Dam KL; Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark. Electronic address: .
Shukla NN; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Cooper TM; Division of Hematology/Oncology, Seattle Children's Hospital, University of Washington, Seattle, WA, USA.
Cuglievan B; Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Heidenreich O; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
Kolb EA; Division of Oncology, Nemours/Alfred I. Dupont Hospital for Children, Wilmington, DE, USA.
Rasouli M; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Department of Pediatric Oncology, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands.
Hasle H; Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark.
Zwaan CM; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Department of Pediatric Oncology, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands.
Pokaż więcej
Źródło:
European journal of medical genetics [Eur J Med Genet] 2023 Dec; Vol. 66 (12), pp. 104869. Date of Electronic Publication: 2023 Oct 29.
Typ publikacji:
Review; Journal Article
MeSH Terms:
Homeodomain Proteins*/genetics
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/genetics
Leukemia, Myeloid, Acute*/metabolism
Humans ; Child ; Myeloid Ecotropic Viral Integration Site 1 Protein ; Myeloid-Lymphoid Leukemia Protein/genetics ; Transcription Factors ; Cell Differentiation
Czasopismo naukowe
Tytuł:
Rationale and design of the Children's Oncology Group study AAML1831 integrated cardiac substudies in pediatric acute myeloid leukemia therapy.
Autorzy:
Leger KJ; Division of Pediatric Hematology/Oncology, Seattle Children's Hospital, University of Washington, Seattle, WA, United States.
Robison N; Division of Pediatric Hematology/Oncology, Seattle Children's Hospital, University of Washington, Seattle, WA, United States.
Narayan HK; Division of Cardiology, Department of Pediatrics, Rady Children's Hospital San Diego, University of California San Diego, La Jolla, CA, United States.
Smith AM; Division of Cardiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Tsega T; Division of Cardiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Chung J; Division of Cardiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Daniels A; Division of Cardiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Chen Z; Division of Cardiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Englefield V; Division of Cardiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Demissei BG; Division of Cardiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Lefebvre B; Division of Cardiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Morrow G; Division of Cardiology, Children's Healthcare of Atlanta, Atlanta, GA, United States.
Dizon I; Division of Cardiology, Seattle Children's Hospital, Seattle, WA, United States.
Gerbing RB; Children's Oncology Group, Monrovia, CA, United States.
Pabari R; Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada.
Getz KD; Division of Oncology, Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
Aplenc R; Division of Oncology, Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
Pollard JA; Division of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Department of Pediatrics, Harvard Medical School, Boston, MA, United States.
Chow EJ; Division of Pediatric Hematology/Oncology, Seattle Children's Hospital, University of Washington, Seattle, WA, United States.; Clinical Research and Public Health Sciences Divisions, Fred Hutchinson Cancer Center, Seattle, WA, United States.
Tang WHW; Department of Cardiovascular Medicine, Heart Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH, United States.
Border WL; Division of Cardiology, Children's Healthcare of Atlanta, Atlanta, GA, United States.; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States.
Sachdeva R; Division of Cardiology, Children's Healthcare of Atlanta, Atlanta, GA, United States.; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States.
Alonzo TA; Children's Oncology Group, Monrovia, CA, United States.; Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.
Kolb EA; Nemours Center for Cancer and Blood Disorders, Alfred I. DuPont Hospital for Children, Wilmington, DE, United States.
Cooper TM; Division of Pediatric Hematology/Oncology, Seattle Children's Hospital, University of Washington, Seattle, WA, United States.
Ky B; Division of Cardiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Pokaż więcej
Źródło:
Frontiers in cardiovascular medicine [Front Cardiovasc Med] 2023 Dec 01; Vol. 10, pp. 1286241. Date of Electronic Publication: 2023 Dec 01 (Print Publication: 2023).
Typ publikacji:
Journal Article
Czasopismo naukowe
Tytuł:
Valosin-containing protein (VCP/p97) is prognostically unfavorable in pediatric AML, and negatively correlates with unfolded protein response proteins IRE1 and GRP78: A report from the Children's Oncology Group.
Autorzy:
Hoff FW; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Qiu Y; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Brown BD; Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Gerbing RB; COG Statistics and Data Center, Monrovia, California, USA.
Leonti AR; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Ries RE; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Gamis AS; Department of Hematology-Oncology, Children's Mercy Hospitals and Clinics, Kansas City, Missouri, USA.
Aplenc R; Division of Pediatric Oncology/Stem Cell Transplant, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Kolb EA; Nemours Center for Cancer and Blood Disorders, Alfred I. DuPont Hospital for Children, Wilmington, Delaware, USA.
Alonzo TA; COG Statistics and Data Center, Monrovia, California, USA.; Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Meshinchi S; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Jenkins GN; Department of Pediatrics, Baylor College of Medicine/Dan L. Duncan Cancer Center and Texas Children's Cancer Center, Houston, Texas, USA.
Horton TM; Department of Pediatrics, Baylor College of Medicine/Dan L. Duncan Cancer Center and Texas Children's Cancer Center, Houston, Texas, USA.
Kornblau SM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Pokaż więcej
Źródło:
Proteomics. Clinical applications [Proteomics Clin Appl] 2023 Nov; Vol. 17 (6), pp. e2200109. Date of Electronic Publication: 2023 Jun 07.
Typ publikacji:
Journal Article
MeSH Terms:
Cell Cycle Proteins*/genetics
Cell Cycle Proteins*/metabolism
Endoplasmic Reticulum Chaperone BiP*
Child ; Humans ; Bortezomib/pharmacology ; Bortezomib/therapeutic use ; Bortezomib/metabolism ; Protein Serine-Threonine Kinases/metabolism ; Unfolded Protein Response ; Valosin Containing Protein/genetics ; Valosin Containing Protein/metabolism
Czasopismo naukowe
Tytuł:
Position paper: The time for cooperative group study of ropeginterferon alfa-2b in young patients with myeloproliferative neoplasms is now.
Autorzy:
Kucine N; Department of Pediatrics, Weill Cornell Medicine, New York, New York, USA.
Jessup JA; PharmaEssentia is in Burlington MA, PharmaEssentia USA Corporation, Burlington, Massachusetts, USA.
Cooper TM; Cancer and Blood Disorders Center, Seattle Children's Hospital, University of Washington, Seattle, Washington, USA.
Urbanski RW; PharmaEssentia is in Burlington MA, PharmaEssentia USA Corporation, Burlington, Massachusetts, USA.
Kolb EA; The Leukemia & Lymphoma Society, Rye Brook, New York, USA.
Resar LMS; Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Pokaż więcej
Źródło:
Pediatric blood & cancer [Pediatr Blood Cancer] 2023 Oct; Vol. 70 (10), pp. e30559. Date of Electronic Publication: 2023 Jul 16.
Typ publikacji:
Journal Article
MeSH Terms:
Polyethylene Glycols*/therapeutic use
Neoplasms*
Humans ; Recombinant Proteins/therapeutic use ; Antiviral Agents
Czasopismo naukowe
Tytuł:
Children's Oncology Group's 2023 blueprint for research: Myeloid neoplasms.
Autorzy:
Cooper TM; Department of Pediatrics, Seattle Children's Hospital Cancer and Blood Disorders Service, University of Washington School of Medicine, Seattle, Washington, USA.
Alonzo TA; Department of Population and Public Health Sciences, University of Southern California, Los Angels, California, USA.
Tasian SK; Department of Pediatrics, Children's Hospital of Philadelphia Division of Oncology and Center for Childhood Cancer Research and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
Kutny MA; Department of Pediatrics, Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Hitzler J; Division of Hematology/Oncology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Ontario, Canada.; Department of pediatrics, Developmental and Stem Cell Biology, The Hospital for Sick Children Research Institute, Toronto, ON, Canada.
Pollard JA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of pediatrics, Division of Hematology/Oncology, Boston Children's Hospital, and Harvard Medical School, Boston, Massachusetts, USA.
Aplenc R; Department of Pediatrics, Children's Hospital of Philadelphia Division of Oncology and Center for Childhood Cancer Research and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
Meshinchi S; Department of Pediatrics, Seattle Children's Hospital Cancer and Blood Disorders Service, University of Washington School of Medicine, Seattle, Washington, USA.; University of Washington, Department of Pediatrics, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Kolb EA; Department of Pediatrics, Nemours Center for Cancer and Blood Disorders, Nemours Children's Health, Wilmington, Delaware, USA.
Pokaż więcej
Źródło:
Pediatric blood & cancer [Pediatr Blood Cancer] 2023 Sep; Vol. 70 Suppl 6, pp. e30584. Date of Electronic Publication: 2023 Jul 21.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
MeSH Terms:
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/genetics
Antineoplastic Agents*/therapeutic use
Hematopoietic Stem Cell Transplantation*
Humans ; Child ; Prognosis ; Sorafenib/therapeutic use ; Gemtuzumab/therapeutic use ; Mutation ; fms-Like Tyrosine Kinase 3/genetics
Czasopismo naukowe
Tytuł:
Comparison of variants in TPMT and NUDT15 between sequencing and genotyping methods in a multistate pediatric institution.
Autorzy:
Cook KJ; Precision Medicine, Nemours Children's Health, Jacksonville, Florida, USA.; Department of Pharmacotherapy and Translational Research, The University of Florida College of Pharmacy, Jacksonville, Florida, USA.
Grusauskas V; Precision Medicine, Nemours Children's Health, Jacksonville, Florida, USA.; Department of Pharmacotherapy and Translational Research, The University of Florida College of Pharmacy, Jacksonville, Florida, USA.
Gloe L; Precision Medicine, Nemours Children's Health, Jacksonville, Florida, USA.; Department of Pharmacotherapy and Translational Research, The University of Florida College of Pharmacy, Jacksonville, Florida, USA.
Duong BQ; Precision Medicine, Nemours Children's Health, Wilmington, Delaware, USA.
Gresh RC; Department of Pediatric Hematology/Oncology, Nemours Children's Health, Wilmington, Delaware, USA.
Kolb EA; Department of Pediatric Hematology/Oncology, Nemours Children's Health, Wilmington, Delaware, USA.
Bansal M; Department of Pediatric Hematology/Oncology, Nemours Children's Health, Jacksonville, Florida, USA.
Bechtel AS; Department of Pediatric Hematology/Oncology, Nemours Children's Health, Jacksonville, Florida, USA.
Nagasubramanian R; Nemours Children's Hospital, Orlando, Florida, USA.
Kirwin SM; Molecular Diagnostics Laboratory, Nemours Children's Health, Wilmington, Delaware, USA.
Blake KV; Precision Medicine, Nemours Children's Health, Jacksonville, Florida, USA.
Seligson ND; Precision Medicine, Nemours Children's Health, Jacksonville, Florida, USA.; Department of Pharmacotherapy and Translational Research, The University of Florida College of Pharmacy, Jacksonville, Florida, USA.
Pokaż więcej
Źródło:
Clinical and translational science [Clin Transl Sci] 2023 Aug; Vol. 16 (8), pp. 1352-1358. Date of Electronic Publication: 2023 Jul 06.
Typ publikacji:
Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:
Azathioprine*/adverse effects
Polymorphism, Genetic*
Humans ; Genetic Testing ; Genotype ; Genotyping Techniques
Czasopismo naukowe
Tytuł:
Comprehensive molecular and clinical characterization of NUP98 fusions in pediatric acute myeloid leukemia.
Autorzy:
Bertrums EJM; Princess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands; Department of Pediatric Oncology/Hematology, Erasmus Medical Center - Sophia Children's Hospital, Rotterdam, the Netherlands; Oncode Institute, Utrecht. .
Smith JL; Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA.
Harmon L; Department of Epigenetics, Van Andel Institute, Grand Rapids, MI.
Ries RE; Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA.
Wang YJ; Department of Translational Genomics, University of Southern California, Los Angeles, CA, USA; Children's Oncology Group, Monrovia, CA.
Alonzo TA; Department of Translational Genomics, University of Southern California, Los Angeles, CA, USA; Children's Oncology Group, Monrovia, CA.
Menssen AJ; Hematologics, Inc, Seattle, WA.
Chisholm KM; Department of Laboratories, Seattle Children's Hospital, Seattle, WA.
Leonti AR; Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA.
Tarlock K; Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, USA; Division of Hematology and Oncology, Seattle Children's Hospital, Seattle, WA.
Ostronoff F; Intermountain Blood and Marrow Transplant and Acute Leukemia Program, Intermountain Healthcare, Salt Lake City, UT.
Pogosova-Agadjanyan EL; Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA.
Kaspers GJL; Princess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands; Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Pediatric Oncology, The Netherlands; Dutch Childhood Oncology Group.
Hasle H; Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark.
Dworzak M; Children's Cancer Research Institute, Medical University of Vienna, Vienna, Austria; St. Anna Kinderspital, Department of Pediatrics, Medical University of Vienna, Vienna.
Walter C; Department of Pediatric Hematology and Oncology, University Hospital Essen, Essen.
Muhlegger N; Children's Cancer Research Institute, Medical University of Vienna, Vienna.
Morerio C; Laboratory of Human Genetics, IRCCS Istituto Giannina Gaslini, Genoa.
Pardo L; Hematologics, Inc, Seattle, WA.
Hirsch B; Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN.
Raimondi S; Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN.
Cooper TM; Division of Hematology and Oncology, Seattle Children's Hospital, Seattle, WA.
Aplenc R; Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA.
Gamis AS; Division of Hematology/Oncology, Children's Mercy Kansas City, Kansas City, MO.
Kolb EA; Nemours Alfred I. duPont Hospital for Children, Wilmington, DE.
Farrar JE; Arkansas Children's Research Institute and Department of Pediatrics, Hematology/Oncology Section, Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR.
Stirewalt D; Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA.
Ma X; Computational Biology Department, St. Jude Children's Research Hospital, Memphis, TN.
Shaw TI; Computational Biology Department, St. Jude Children's Research Hospital, Memphis, TN.
Furlan SN; Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA.
Brodersen LE; Hematologics, Inc, Seattle, WA.
Loken MR; Hematologics, Inc, Seattle, WA.
Van den Heuvel-Eibrink MM; Princess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands; Utrecht University, Utrecht.
Zwaan CM; Princess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands; Department of Pediatric Oncology/Hematology, Erasmus Medical Center - Sophia Children's Hospital, Rotterdam, the Netherlands; Dutch Childhood Oncology Group.
Triche TJ; Department of Epigenetics, Van Andel Institute, Grand Rapids, MI, USA; Department of Translational Genomics, University of Southern California, Los Angeles, CA, USA; Department of Pediatrics, Michigan State University College of Human Medicine, Grand Rapids, MI.
Goemans BF; Princess Maxima Center for Pediatric Oncology, Utrecht.
Meshinchi S; Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, USA; Children's Oncology Group, Monrovia, CA, USA; Division of Hematology and Oncology, Seattle Children's Hospital, Seattle, WA. .
Pokaż więcej
Źródło:
Haematologica [Haematologica] 2023 Aug 01; Vol. 108 (8), pp. 2044-2058. Date of Electronic Publication: 2023 Aug 01.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Leukemia, Myeloid, Acute*/genetics
Child ; Young Adult ; Humans ; Mutation ; Nuclear Pore Complex Proteins/genetics ; Gene Expression Profiling ; Retinoblastoma-Binding Protein 2/genetics
Czasopismo naukowe
Tytuł:
Bone Marrow Microenvironment-Induced Chemoprotection in KMT2A Rearranged Pediatric AML Is Overcome by Azacitidine-Panobinostat Combination.
Autorzy:
Lehner KM; Lisa Dean Moseley Foundation Institute for Cancer and Blood Disorders, Nemours Children's Hospital, Wilmington, DE 19803, USA.; Department of Biological Sciences, University of Delaware, Newark, DE 19716, USA.
Gopalakrishnapillai A; Lisa Dean Moseley Foundation Institute for Cancer and Blood Disorders, Nemours Children's Hospital, Wilmington, DE 19803, USA.; Department of Biological Sciences, University of Delaware, Newark, DE 19716, USA.
Kolb EA; Lisa Dean Moseley Foundation Institute for Cancer and Blood Disorders, Nemours Children's Hospital, Wilmington, DE 19803, USA.
Barwe SP; Lisa Dean Moseley Foundation Institute for Cancer and Blood Disorders, Nemours Children's Hospital, Wilmington, DE 19803, USA.; Department of Biological Sciences, University of Delaware, Newark, DE 19716, USA.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2023 Jun 08; Vol. 15 (12). Date of Electronic Publication: 2023 Jun 08.
Typ publikacji:
Journal Article
Czasopismo naukowe
Tytuł:
Machine learning classifier approaches for predicting response to RTK-type-III inhibitors demonstrate high accuracy using transcriptomic signatures and ex vivo data.
Autorzy:
Ferrato MH; University of Delaware, Newark, DE 19716, USA.
Marsh AG; University of Delaware, Newark, DE 19716, USA.
Franke KR; Nemours Children Health System, Wilmington, DE 19803, USA.
Huang BJ; Department of Pediatrics, University of California San Francisco, San Francisco, CA 94143, USA.; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94143, USA.
Kolb EA; Nemours Children Health System, Wilmington, DE 19803, USA.
DeRyckere D; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.
Grahm DK; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.
Chandrasekaran S; University of Delaware, Newark, DE 19716, USA.
Crowgey EL; Nemours Children Health System, Wilmington, DE 19803, USA.
Pokaż więcej
Źródło:
Bioinformatics advances [Bioinform Adv] 2023 Mar 22; Vol. 3 (1), pp. vbad034. Date of Electronic Publication: 2023 Mar 22 (Print Publication: 2023).
Typ publikacji:
Journal Article
Czasopismo naukowe
Tytuł:
Aberrant T-cell exhaustion in severe combined immunodeficiency survivors with poor T-cell reconstitution after transplantation.
Autorzy:
Labrosse R; Pediatric Immunology and Rheumatology Division, Department of Pediatrics, University of Montreal, Montreal, Quebec, Canada.
Boufaied I; Cytokines and Adaptive Immunity Laboratory, Sainte-Justine University Hospital Research Center, Montreal, Quebec, Canada.
Bourdin B; Cytokines and Adaptive Immunity Laboratory, Sainte-Justine University Hospital Research Center, Montreal, Quebec, Canada.
Gona S; Genetics, Genomics, and Systems Biology, Department of Medicine, Section of Genetic Medicine, University of Chicago, Chicago, Ill.
Randolph HE; Genetics, Genomics, and Systems Biology, Department of Medicine, Section of Genetic Medicine, University of Chicago, Chicago, Ill.
Logan BR; Division of Biostatistics, Medical College of Wisconsin, Milwaukee, Wis.
Bourbonnais S; Cytokines and Adaptive Immunity Laboratory, Sainte-Justine University Hospital Research Center, Montreal, Quebec, Canada.
Berthe C; Cytokines and Adaptive Immunity Laboratory, Sainte-Justine University Hospital Research Center, Montreal, Quebec, Canada.
Chan W; Division of Allergy, Immunology, and Blood and Marrow Transplantation, Department of Pediatrics, University of California, San Francisco, and UCSF Benioff Children's Hospital, San Francisco, Calif.
Buckley RH; Duke University Medical Center, Durham, NC.
Parrott RE; Duke University Medical Center, Durham, NC.
Cuvelier GDE; Manitoba Blood and Marrow Transplant Program, CancerCare Manitoba, University of Manitoba, Winnipeg, Manitoba, Canada.
Kapoor N; Blood and Marrow Transplant Program, Division of Hematology, Oncology, and Blood and Marrow Transplantation, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, Calif.
Chandra S; Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, and the Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio.
Dávila Saldaña BJ; Division of Blood and Marrow Transplantation, Children's National Hospital, George Washington University School of Medicine and Health Sciences, Washington, DC.
Eissa H; Children's Hospital of Colorado, University of Colorado School of Medicine, Aurora, Colo.
Goldman FD; Department of Pediatrics, The University of Alabama at Birmingham, Birmingham, Ala.
Heimall J; Allergy and Immunology, The Children's Hospital of Philadelphia, Philadelphia, Pa.
O'Reilly R; Department of Pediatrics, Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY.
Chaudhury S; Division of Hematology, Oncology, and Stem Cell Transplantation, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, Ill.
Kolb EA; Nemours Children's Health, Center for Cancer and Blood Disorders, Wilmington, Del.
Shenoy S; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Washington University School of Medicine, St Louis, Mo.
Griffith LM; Division of Allergy, Immunology, and Transplantation, National Institutes of Health, Bethesda, Md.
Pulsipher M; Blood and Marrow Transplant Program, Division of Hematology, Oncology, and Blood and Marrow Transplantation, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, Calif.
Kohn DB; Pediatrics, David Geffen School of Medicine at University of California, Los Angeles, Calif.
Notarangelo LD; Laboratory of Clinical Immunology and Microbiology, National Institutes of Health, Bethesda, Md.
Pai SY; Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Md.
Cowan MJ; Division of Allergy, Immunology, and Blood and Marrow Transplantation, Department of Pediatrics, University of California, San Francisco, and UCSF Benioff Children's Hospital, San Francisco, Calif.
Dvorak CC; Division of Allergy, Immunology, and Blood and Marrow Transplantation, Department of Pediatrics, University of California, San Francisco, and UCSF Benioff Children's Hospital, San Francisco, Calif.
Haddad É; Pediatric Immunology and Rheumatology Division, Department of Pediatrics, University of Montreal, Montreal, Quebec, Canada.
Puck JM; Division of Allergy, Immunology, and Blood and Marrow Transplantation, Department of Pediatrics, University of California, San Francisco, and UCSF Benioff Children's Hospital, San Francisco, Calif.
Barreiro LB; Genetics, Genomics, and Systems Biology, Department of Medicine, Section of Genetic Medicine, University of Chicago, Chicago, Ill.
Decaluwe H; Pediatric Immunology and Rheumatology Division, Department of Pediatrics, University of Montreal, Montreal, Quebec, Canada; Cytokines and Adaptive Immunity Laboratory, Sainte-Justine University Hospital Research Center, Montreal, Quebec, Canada. Electronic address: .
Pokaż więcej
Źródło:
The Journal of allergy and clinical immunology [J Allergy Clin Immunol] 2023 Jan; Vol. 151 (1), pp. 260-271. Date of Electronic Publication: 2022 Aug 17.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural
MeSH Terms:
Severe Combined Immunodeficiency*
Hematopoietic Stem Cell Transplantation*
Lymphopenia*
Humans ; CD8-Positive T-Lymphocytes ; T-Cell Exhaustion ; Receptors, Antigen, T-Cell
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies